

# **Dupuytren's Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Diagnosis {Physical Examination, X-ray}, Treatment {Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others}), By Disease Type (Type I, Type II, Type III), By End-use (Hospitals, Clinics, Academic & Research Institute, Others), By Region, Competition By Type (Bladder, Piston, Diaphragm, and Spring), By Application (Blow Out Preventers (BOP), Mud Pumps, Offshore Rigs, and Others), By Deployment (Onshore, Offshore), By Region and Competition**

<https://marketpublishers.com/r/DC340674A9ECEN.html>

Date: October 2023

Pages: 171

Price: US\$ 4,900.00 (Single User License)

ID: DC340674A9ECEN

## **Abstracts**

The Global Dupuytren's Disease Market achieved a valuation of USD 4.23 Billion in 2022 and is poised for robust growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 4.31% through 2028 and expected to reach at USD 5.41 Billion in 2028. Dupuytren's disease, also known as Dupuytren's contracture, is a progressive condition affecting the connective tissue beneath the skin of the palm and fingers. Named after the French surgeon Baron Guillaume Dupuytren, who first described it in the 19th century, this condition primarily causes the fingers to bend towards the palm, resulting in functional limitations.

Key Market Drivers:

1. **Rising Prevalence and Awareness:** The prevalence of Dupuytren's disease has shown a consistent increase over the years. This condition predominantly affects individuals of Northern European descent, with a higher incidence observed in men and those over the age of 50. As the global population ages and awareness about this condition increases, more patients are seeking medical attention. This growing patient pool is a significant driver of market growth, generating demand for both diagnosis and treatment options. The rising prevalence of Dupuytren's disease has led to greater awareness of this often-overlooked ailment. Previously, many individuals with early symptoms or mild contractures might not have sought medical attention, attributing their discomfort to age or other minor causes. However, a shift in public and medical awareness has paved the way for earlier diagnosis and intervention.

2. **Advancements in Treatment Options:** In the field of medicine, progress is often marked by the development of innovative treatment approaches. Dupuytren's disease has not been an exception. Traditionally, surgical procedures were the primary treatment for severe cases, involving the excision of the abnormal tissue causing finger contractures. However, as medical science has evolved, a plethora of non-surgical and minimally invasive treatments have emerged, providing patients with a wider array of choices. Enzyme-based treatments, such as collagenase injections, have gained popularity as a less invasive alternative. These injections help break down the collagen that forms the cords, allowing for easier manipulation of the fingers and potentially delaying or obviating the need for surgery. Needle aponeurotomy, a minimally invasive procedure involving the use of a needle to puncture and release the cords, has also gained traction. Targeted drug therapies that modify the underlying processes contributing to Dupuytren's disease are being explored, potentially halting its progression or preventing recurrence after treatment.

3. **Research and Collaboration:** Collaborative efforts between medical researchers, pharmaceutical companies, and healthcare institutions are playing a pivotal role in advancing the Dupuytren's disease market. Increased research funding and initiatives have allowed for a deeper understanding of the disease's genetic and molecular underpinnings, leading to the development of more precise and effective treatment strategies. Research into the genetic basis of Dupuytren's disease has led to the exploration of gene therapies, with gene editing offering the potential to alter genetic factors contributing to the condition. Interdisciplinary collaboration among researchers, medical professionals, geneticists, and pharmacologists fosters a comprehensive understanding of the condition, accelerating the pace of discovery. Patient advocacy groups and informed patients contribute to research efforts and the dissemination of

information about Dupuytren's disease.

#### Key Market Challenges:

1. **Limited Awareness and Diagnosis:** Despite the increasing prevalence of Dupuytren's disease, limited awareness remains a significant challenge. Many individuals, especially in the early stages of the condition, may mistake the symptoms for normal signs of aging or other minor discomforts. As a result, diagnosis is often delayed, impeding timely intervention. Comprehensive educational initiatives targeting both medical practitioners and the general public are needed to increase awareness about the symptoms, risk factors, and available treatments.

2. **Access to Specialized Care:** The demand for Dupuytren's disease treatments highlights the need for specialized medical care. Surgeons, physiotherapists, and hand therapists with expertise in treating the condition are essential for optimal patient outcomes. However, access to specialized care can be limited in certain regions, especially in rural or underserved areas. Efforts to establish referral pathways and enhance collaboration between general practitioners and specialists are needed. Telemedicine and telehealth initiatives could bridge the gap by connecting patients with experts remotely.

3. **Treatment Costs and Reimbursement:** The economic burden of Dupuytren's disease treatment can be substantial, presenting a barrier to patient access. Some treatment options, including non-surgical approaches, can come with high costs. Navigating insurance coverage and reimbursement complexities is another challenge, as some treatments might not be covered by insurance plans, leaving patients to bear the financial burden. Collaboration between healthcare providers, insurance companies, and policymakers is required to ensure that effective treatments are accessible to a broader patient population.

#### Key Market Trends:

1. **Patient-Centric Healthcare Approach:** A shift toward patient-centric healthcare is transforming the medical field. Patients are becoming active participants in their treatment journeys, demanding options that align with their preferences and lifestyles. This trend is driving the development of a diverse range of treatment modalities to cater to varying patient needs.

2. **Advancements in Minimally Invasive Techniques:** Minimally invasive medical

techniques are revolutionizing patient care in the Dupuytren's disease market. These techniques offer quicker recovery times, reduced scarring, and often allow patients to return to their daily activities sooner. Enzyme-based treatments and needle aponeurotomy are attracting patients seeking less invasive options.

3. Research into Targeted Therapies: Research into the genetic and molecular mechanisms underlying Dupuytren's disease is paving the way for targeted therapies. These treatments have the potential to halt or slow down the progression of the disease, going beyond symptom management.

#### Segmental Insights:

Disease Type Insights: In 2022,

the Dupuytren's Disease Market was dominated by the disease type II segment. Type II Dupuytren's is characterized by involvement of the palmar fascia and digital cords, resulting in finger flexion abnormalities. Recent studies have shown that type II accounts for a significant share of diagnosed cases, highlighting its higher prevalence and impact.

Type Insights: In 2022, the Dupuytren's Disease Market was dominated by the treatment segment. This dominance is attributed to increased efforts to create powerful therapeutic options for managing the condition and improving patients' well-being. Pharmaceutical companies and medical equipment manufacturers have been working on innovative treatment modalities through research and development initiatives.

Regional Insights: The Europe region has established itself as the leader in the Global Dupuytren's Disease Market and is anticipated to maintain this position throughout the forecast period. Factors contributing to this leadership include increased disease prevalence, established healthcare systems with advanced infrastructure, and robust research and development programs.

#### Key Market Players

Novartis AG

Pfizer Inc.

Bayer AG

Nantong Jinghua Pharmaceutical Co., Ltd

Actiza Pharmaceutical Private Limited

Endo International plc

Spear Pharmaceuticals

Hikma Pharmaceuticals PLC

Bristol-Myers Squibb

Glaxosmithkline PLC.

#### Report Scope:

In this report, the Global Dupuytren's Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

#### Dupuytren's Disease Market, By Type:

Diagnosis {Physical Examination, X-ray}

Treatment {Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others}

#### Dupuytren's Disease Market, By Disease Type:

Type I

Type II

Type III

#### Dupuytren's Disease Market, By End-use:

Hospitals

Clinics

Academic & Research Institute

Others

Global Dupuytren's Disease Market, By Region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dupuytren's Disease Market.

Available Customizations:

Global Dupuytren's Disease Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### **1. PRODUCT OVERVIEW**

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### **2. RESEARCH METHODOLOGY**

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### **3. EXECUTIVE SUMMARY**

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### **4. VOICE OF CUSTOMER**

### **5. CLINICAL TRIAL ANALYSIS**

- 5.1. Ongoing Clinical Trials
- 5.2. Completed Clinical Trials
- 5.3. Terminated Clinical Trials
- 5.4. Breakdown of Pipeline, By Development Phase
- 5.5. Breakdown of Pipeline, By Status
- 5.6. Breakdown of Pipeline, By Study Application



5.7. Breakdown of Pipeline, By Region

5.8. Clinical Trials Heat Map

## **6. DUPUYTREN'S DISEASE MARKET OUTLOOK**

6.1. Market Size & Forecast

6.1.1. By Value

6.1.2. Market Share & Forecast

6.1.3. By Type (Diagnosis {Physical Examination, X-ray}, Treatment {Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others})

6.1.4. By Disease Type (Type I, Type II, Type III)

6.1.5. By End-use (Hospitals, Clinics, Academic & Research Institute, Others)

6.1.6. By Company (2022)

6.1.7. By Region

6.2. Market Map

## **7. NORTH AMERICA DUPUYTREN'S DISEASE MARKET OUTLOOK**

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type

7.2.2. By Disease Type

7.2.3. By End-use

7.2.4. By Country

7.3. North America: Country Analysis

7.3.1. United States Dupuytren's Disease Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type

7.3.1.2.2. By Disease Type

7.3.1.2.3. By End-Use

7.3.2. Mexico Dupuytren's Disease Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type

- 7.3.2.2.2. By Disease Type
- 7.3.2.2.3. By End-Use
- 7.3.3. Canada Dupuytren's Disease Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Disease Type
    - 7.3.3.2.3. By End-Use

## **8. EUROPE DUPUYTREN'S DISEASE MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Type
  - 8.2.2. By Disease Type
  - 8.2.3. By End-use
  - 8.2.4. By Country
- 8.3. Europe: Country Analysis
  - 8.3.1. France Dupuytren's Disease Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Type
      - 8.3.1.2.2. By Disease Type
      - 8.3.1.2.3. By End-Use
  - 8.3.2. Germany Dupuytren's Disease Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Type
      - 8.3.2.2.2. By Disease Type
      - 8.3.2.2.3. By End-Use
  - 8.3.3. United Kingdom Dupuytren's Disease Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Type

- 8.3.3.2.2. By Disease Type
- 8.3.3.2.3. By End-Use
- 8.3.4. Italy Dupuytren's Disease Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Disease Type
    - 8.3.4.2.3. By End-Use
- 8.3.5. Spain Dupuytren's Disease Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Disease Type
    - 8.3.5.2.3. By End-Use

## **9. ASIA-PACIFIC DUPUYTREN'S DISEASE MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Type
  - 9.2.2. By Disease Type
  - 9.2.3. By End-use
  - 9.2.4. By Country
- 9.3. Asia-Pacific: Country Analysis
  - 9.3.1. China Dupuytren's Disease Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Type
      - 9.3.1.2.2. By Disease Type
      - 9.3.1.2.3. By End-Use
  - 9.3.2. India Dupuytren's Disease Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Type

- 9.3.2.2.2. By Disease Type
- 9.3.2.2.3. By End-Use
- 9.3.3. South Korea Dupuytren's Disease Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Disease Type
    - 9.3.3.2.3. By End-Use
- 9.3.4. Japan Dupuytren's Disease Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Type
    - 9.3.4.2.2. By Disease Type
    - 9.3.4.2.3. By End-Use
- 9.3.5. Australia Dupuytren's Disease Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By Type
    - 9.3.5.2.2. By Disease Type
    - 9.3.5.2.3. By End-Use

## **10. SOUTH AMERICA DUPUYTREN'S DISEASE MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Type
  - 10.2.2. By Disease Type
  - 10.2.3. By End-use
  - 10.2.4. By Country
- 10.3. South America: Country Analysis
  - 10.3.1. Brazil Dupuytren's Disease Market Outlook
    - 10.3.1.1. Market Size & Forecast
      - 10.3.1.1.1. By Value
    - 10.3.1.2. Market Share & Forecast
      - 10.3.1.2.1. By Type

- 10.3.1.2.2. By Disease Type
- 10.3.1.2.3. By End-Use
- 10.3.2. Argentina Dupuytren's Disease Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Disease Type
    - 10.3.2.2.3. By End-Use
- 10.3.3. Colombia Dupuytren's Disease Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Disease Type
    - 10.3.3.2.3. By End-Use

## **11. MIDDLE EAST AND AFRICA DUPUYTREN'S DISEASE MARKET OUTLOOK**

- 11.1. Market Size & Forecast
  - 11.1.1. By Value
- 11.2. Market Share & Forecast
  - 11.2.1. By Type
  - 11.2.2. By Disease Type
  - 11.2.3. By End-use
  - 11.2.4. By Country
- 11.3. MEA: Country Analysis
  - 11.3.1. South Africa Dupuytren's Disease Market Outlook
    - 11.3.1.1. Market Size & Forecast
      - 11.3.1.1.1. By Value
    - 11.3.1.2. Market Share & Forecast
      - 11.3.1.2.1. By Type
      - 11.3.1.2.2. By Disease Type
      - 11.3.1.2.3. By End-Use
  - 11.3.2. Saudi Arabia Dupuytren's Disease Market Outlook
    - 11.3.2.1. Market Size & Forecast
      - 11.3.2.1.1. By Value
    - 11.3.2.2. Market Share & Forecast
      - 11.3.2.2.1. By Type

- 11.3.2.2.2. By Disease Type
- 11.3.2.2.3. By End-Use
- 11.3.3. UAE Dupuytren's Disease Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Type
    - 11.3.3.2.2. By Disease Type
    - 11.3.3.2.3. By End-Use

## **12. MARKET DYNAMICS**

- 12.1. Drivers
- 12.2. Challenges

## **13. MARKET TRENDS & DEVELOPMENTS**

- 13.1. Recent Developments
- 13.2. Product Launches
- 13.3. Mergers & Acquisitions

## **14. PESTLE ANALYSIS**

## **15. PORTER'S FIVE FORCES ANALYSIS**

- 15.1. Competition in the Industry
- 15.2. Potential of New Entrants
- 15.3. Power of Suppliers
- 15.4. Power of Customers
- 15.5. Threat of Substitute Product

## **16. COMPETITIVE LANDSCAPE**

- 16.1. Business Overview
- 16.2. Company Snapshot
- 16.3. Products & Services
- 16.4. Financials (In case of listed companies)
- 16.5. Recent Developments

## 16.6. SWOT Analysis

16.6.1. Novartis AG

16.6.2. Pfizer Inc.

16.6.3. Bayer AG

16.6.4. Nantong Jinghua Pharmaceutical Co., Ltd

16.6.5. Actiza Pharmaceutical Private Limited

16.6.6. Endo International plc

16.6.7. Spear Pharmaceuticals

16.6.8. Hikma Pharmaceuticals PLC

16.6.9. Bristol-Myers Squibb

16.6.10. Glaxosmithkline PLC.

## 17. STRATEGIC RECOMMENDATIONS

## I would like to order

Product name: Dupuytren's Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Diagnosis {Physical Examination, X-ray}, Treatment {Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others}), By Disease Type (Type I, Type II, Type III), By End-use (Hospitals, Clinics, Academic & Research Institute, Others), By Region, Competition By Type (Bladder, Piston, Diaphragm, and Spring), By Application (Blow Out Preventers (BOP), Mud Pumps, Offshore Rigs, and Others), By Deployment (Onshore, Offshore), By Region and Competition

Product link: <https://marketpublishers.com/r/DC340674A9ECEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DC340674A9ECEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_



Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970